Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 8, 2026, reports a significant regulatory milestone for the company's respiratory portfolio. The filing announces the approval of Exdensur (depemokimab) by China's National Medical Products Administration (NMPA) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients.
Key Financial Metrics
The filing text does not provide specific financial values, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a product approval event rather than a periodic financial statement.
Material Changes and Developments
- Regulatory Approval: Exdensur received NMPA approval in China as an add-on therapy with intranasal corticosteroids for adult patients with CRSwNP who have inadequate disease control from systemic corticosteroids and/or surgery.
- Market Position: Exdensur is now the first and only ultra-long-acting biologic approved in China for CRSwNP.
- Clinical Evidence: Approval was based on the ANCHOR-1 and ANCHOR-2 Phase III trials, which demonstrated statistically significant improvements in nasal polyp size and nasal obstruction compared to placebo plus standard of care.
- Global Footprint: This approval expands on recent approvals for Exdensur in severe asthma in China and the US, as well as approvals for both severe asthma and CRSwNP in Japan, the EU, and the UK.
Outlook, Management Commentary, and Risks
Management Commentary: Kaivan Khavandi, SVP of R&D Head Respiratory, Immunology & Inflammation, stated that the approval could "redefine care" by protecting patients from debilitating symptoms with just two doses per year. He highlighted the unmet need, noting that almost half of CRSwNP patients remain uncontrolled and up to 85% have underlying type 2 inflammation.
Pipeline and Future Outlook: Depemokimab is currently being evaluated in Phase III trials for other type 2 inflammatory diseases, including eosinophilic granulomatosis with polyangiitis (EGPA), hyper eosinophilic syndrome (HES), and COPD (ENDURA-1, ENDURA-2, and VIGILANT trials).
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2025.
Key Facts for Investor Verification
- Verify the commercial launch timeline and reimbursement status of Exdensur for CRSwNP in China.
- Monitor upcoming data readouts for the OCEAN, DESTINY, ENDURA, and VIGILANT trials to assess the drug's potential in EGPA, HES, and COPD.
- Review the competitive landscape for ultra-long-acting biologics in the Chinese respiratory market.
- Confirm the safety profile of depemokimab in real-world settings, as the filing notes side effects were similar to placebo in trials.